1.Clinical application of the peripheral stimulation in the obturator nerve block used in the TURBt
Yong YANG ; Yong XU ; Bao-Fa HONG ; Hong ZHOU ;
Cancer Research and Clinic 1999;0(05):-
Objective Observe the results and reality of the peripheral nerve stimulator in the obtu- rator nerve block in TURBt.Methods 18 cases received the peripheral nerve stimulator in obturator nerve block before TURBt.Results In 17cases obturator nerve reflection vanished;lcase had a little symptom of adductor spasm.Conclusion Obturator nerve block with the help of the nerve stimulator can increase the achievement and quality of obturator nerve block and avoid some complications caused by obturator nerve re- flection in TURBt,such as perforation of bladder and injury of nerve and vessel.
2.Correlation of Microinflammation,Nutrition and Common Carotid Arterial Intima-Media Thickness
qian, LI ; gen-fa, WANG ; yong-wei, ZHOU ; wei, CHEN
Journal of Shanghai Jiaotong University(Medical Science) 2006;0(07):-
Objective To study the relationship of microinflammation,nutrition and common carotid artery intima-media thickness(CCA-IMT) for the early prevention and interference of ischemic stroke. Methods(CCA-IMT was) measured by carotid arterial ultrasound in 250 elderly subjects.The levels of serum high-sensitivity C-(reactive) protein(hsCRP),ferritin,albumin,pre-albumin and transferrin were assayed at the same time.According to the results of CCA-IMT,all the subjects were divided into five groups:
3.Effects of Aminoguanidine on Blood Brain Barrier and Brain Ischemic Damage during Reperfusion of Cerebral Ischemia in Rats
wen-an, WANG ; geng-fa, WANG ; yong-wei, ZHOU ; jie, CHENG
Journal of Shanghai Jiaotong University(Medical Science) 2006;0(07):-
Objective To evaluate the therapeutic effects of aminoguanidine(AG) on cerebral ischemia-reperfusion damage in rats. Methods The intravascular thread models with 2 h of occlusion and 22 h of reperfusion were made in the rats.The brain infarction size and the degree of blood brain barrier(BBB) disruption in the ischemic regions were evaluated by staining with 2,3,5-triphenyl tetrazolium chloride and observing with Evans blue fluorescence microscope.HE staining was utilized for observing neutrophil infiltration. Results The brain infarction(volume,) the area of BBB disruption and the degree of neutrophil infiltration were dramatically decreased in the treatment group as compared to the control group(P
4.miRNA-101 inhibits the expression of the enhancer of zeste homolog 2 in androgen-independent prostate cancer LNCaP cell line.
Jian-xin LIU ; Qi-fa ZHANG ; Chang-hai TIAN ; Yong ZHANG ; Xiao-zhou HAN ; Hao GUO
National Journal of Andrology 2015;21(6):500-503
OBJECTIVETo investigate the effect of miRNA-101 on the expression of the enhancer of zeste homolog 2 (EXH2) in human androgen-independent prostated cancer LNCaP cells.
METHODSWe divided LNCaP cells into a blank control, a negative control, and a miRNA-l01 transfection group, constructed the vector by transfecting synthetic miRNA-101 mimics into the LNCaP cells, and evaluated the efficiency of transfection by fluorescence microscopy. Then we determined the expression level of EZH2 mRNA by qRT-PCR in the three groups of cells and that of the EZH2 protein in the negative control and transfection groups by Western blot.
RESULTSGreen fluorescence signals were observed in over 70% of the LNCaP cells in the transfection group after 24 hours of transfection. At 72 hours, the expression of miRNA-101 was significantly upregulated in the transfected cells (P < 0.01), that of EZH2 mRNA was remarkably lower in the transfection group (0.01 ± 0.10) than in the blank control (0.95 ± 0.40) and negative control (0.86 ± 0.30) groups (both P < 0.01), and that of the EZH2 protein was increased in the negative control but decreased in the transfection group with the extension of culture time.
CONCLUSIONmiRNA-101, with its inhibitory effect on the expression of EZH2 in LNCaP cells, is a potential biotherapeutic for prostate cancer.
Androgens ; Cell Line, Tumor ; Enhancer of Zeste Homolog 2 Protein ; Genetic Vectors ; Humans ; Male ; MicroRNAs ; physiology ; Polycomb Repressive Complex 2 ; genetics ; metabolism ; Prostatic Neoplasms ; metabolism ; RNA, Messenger ; metabolism ; Transfection
5.Effect of thyroid hormone level on the expression of synaptotagmin Ⅰ in adult rat hippocampus
Ning-ning, ZHU ; Xue-mei, JIA ; Chun-lei, LIU ; Jing-zhou, HE ; Yong-xia, XU ; De-fa, ZHU
Chinese Journal of Endemiology 2009;28(3):255-258
Objective To observe the effect of different thyroid hormone level on the expression of synaptotagmin Ⅰ(Syt Ⅰ) in adult rat hippocampus. Methods All 28 adult male SD rats were assigned randomly into hypothyroid, hyperthyroid and control group, hypothyroid group was established by daily intraperitoneal injections with propylthiou raci(PTU, 10.0 mg/kg body weight) for 6 weeks and hyperthyroid group with L-Thyroxine (L-T4, 0.5 mg/kg body weight) for 3 weeks. Radioimmunity method was used to assay the levels of serum T3 and T4, immunohistochemical S-P technology to assay the levels of Syt Ⅰ protein in hippoeampus CA1, CA3 and dentate gyrus (DG). The layers analyzed in the different subfields include the polymorphic cell layer(the stratum oriens, SO), pyramidal cell layer(PCL), stratum radiatum (SR), lacunosum-molecular layer (SLM) in CA1 and CA3, granular cell layer(GL) and molecular layer(ML) in DG. Results The levels of serum T3 and T4[(0.34±0.12), (41.03± 11.37)nmol/L]in the hypothyroid rats were significantly lower than those in the control group[(0.65±0.15), (55.20±10.68)nmol/L, P < 0.01 or < 0.05], and the positive granule of Syt Ⅰ was significantly lower in PCL and SR of CA1 and CA3, GL of DG. The average optical value responsible for Syt Ⅰ immunoreactivity was obviously reduced in SO(0.048±0.007), PCL(0.299±0.035), SR(0.042±0.007), SLM(0.038±0.006) of CA1, PCL(0.085± 0.019), SR(0.040±0.011), SLM (0.038±0.006) of CA3, GL (0.076±0.019) of DG than normal controls (0.068± 0.014, 0.376±0.053, 0.053±0.008,0.056±0.009,0.118±0.026,0.052±0.010,0.053±0.009,0.099±0.015; P< 0.01 or < 0.05). Serum T3 and T4 levels [(1.43±0.30), (157.18±19.95)nmol/L]of hyperthyroid rats were significantly higher than those of control group(P < 0.01). The value was reduced in PCL(0.322±0.050), SR(0.039±0.006), SLM (0.042±0.006) of CA1, PCL(0.098±0.034), SR(0.046±0.013), SLM(0.046±0.010) of CA3 and GL(0.085± 0.024), ML (0.042±0.009) of DG (P < 0.05 or < 0.01). Conclusion Adult-onset of hypothyroidism and hyperthyroidism can reversibly decrease the expression of Syt Ⅰ in CA1, CA3 and DG regions of hippocampus.
6.Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34.
He-ping KAN ; Yu WANG ; Yong-fa TAN ; Jie ZHOU
Journal of Southern Medical University 2010;30(8):1930-1934
OBJECTIVETo study the therapeutic effects of Nexavar on liver cancer and its relation to the expressions of Ki-67 and CD34.
METHODSTwenty-eight patients with liver cancer were treated with Nexavar. The therapeutic efficacy of Nexavar on liver cancer was observed. Liver cancer tissues were examined for the expressions of Ki-67 and CD34 by immunohistochemistry. Microvessel density (MVD) was calculated according to the expression of CD34.
RESULTSOf 28 patients, none achieved a complete response (CR), 12 had a partial response (PR), 7 had stable disease (SD), and 9 progressive disease (PD). The efficacy of Nexavar was associated significantly with Ki-67 expression. The mean MVD count was 346.03-/+146.98 in PR patients, and 89.14-/+45.66 in PD patients. There was a significant difference in MVD between PR and PD patients.
CONCLUSIONThere is a better efficacy of Nexavar in treatment of liver cancer in the patients who had Ki-67-positive expression and high MVD count.
Adult ; Aged ; Antigens, CD34 ; metabolism ; Antineoplastic Agents ; therapeutic use ; Female ; Humans ; Ki-67 Antigen ; metabolism ; Liver Neoplasms ; drug therapy ; metabolism ; Male ; Middle Aged ; Niacinamide ; analogs & derivatives ; therapeutic use ; Phenylurea Compounds ; therapeutic use
7.Preliminary report for treatment of discogenic low back pain with combined percutaneous laser and O2-O3 mixture.
Bo ZHAO ; Gao-Hai SHAO ; Yu YU ; Yong-Fa ZHOU ; Bin ZHONG ; Chao HE
China Journal of Orthopaedics and Traumatology 2008;21(5):391-392
OBJECTIVETo evaluate the efficacy of percutaneous laser and O2-O3 mixture in treating chronic discogenic low back pain.
METHODSThere were 48 patients included 32 male and 16 female with the mean age of 43.5 years (range, from 21 to 66 years). The duration of symptoms was more than 6 months, all patients were treated with percutaneous laser and O2-O3 mixture under TV monitoring.
RESULTSForty-eight patients followed-up showed no severe complications. At 1 week follow up, 8 cases were evaluated as excellent, 28 as good, 8 as fair and 4 as poor by Macnab standard. The excellent and good rate reached 75%. At 3 months follow up, 17 cases were evaluated as excellent, 23 as good, 6 as fair and 2 as poor with the excellent and good rate of 83.3%. At 6 months follow up, 20 cases were evaluated as excellent, 22 as good, 4 as fair and 2 as poor with a total effective rate of 87.5%. At 12 months follow up, 21 cases were evaluated as excellent, 22 as good, 4 as fair and 1 as poor with a total effective rate of 89.6%.
CONCLUSIONCombined percutaneous laser and O3-O3 mixture is an effective and safe method in treating discogenic low back pain.
Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Laser Therapy ; Low Back Pain ; radiotherapy ; Male ; Middle Aged ; Ozone ; therapeutic use ; Treatment Outcome
8.Effect of immunonanoparticles loaded with adriamycin on multidrug-resistant liver cancer in nude mice.
He-ping KAN ; Yu WANG ; Yong-fa TAN ; Jie ZHOU
Journal of Southern Medical University 2009;29(8):1617-1619
OBJECTIVETo observe the effect of the immunonanoparticles loaded with adriamycin in reversing multidrug resistance (MDR) in liver cancer in a nude mouse model and explore the possible mechanisms.
METHODSThe cytotoxicity of adriamycin, adriamycin-loaded nanoparticles, and adriamycin-loaded immunonanoparticles was assessed in a nude mouse model bearing implant tumors of adriamycin-resistant hepatoma cell line SMMC-7721/ADM. The concentration of adriamycin in the tumor tissue was determined.
RESULTSAdriamycin-loaded immunonanoparticles showed significantly stronger cytotoxicity against the implant tumors of SMMC-7721/ADM than adriamycin-loaded nanoparticles and adriamycin. Administration of adriamycin-loaded immunonanoparticles resulted in significantly higher drug concentrations in the tumor tissue than adriamycin-loaded nanoparticles and adriamycin.
CONCLUSIONAdriamycin-loaded immunonanoparticles may reverse the MDR of liver cancers in vivo probably resulting from the close binding of the particles with the tumor cells to produce a high local concentration of adriamycin in the tumors.
Animals ; Cell Line, Tumor ; Doxorubicin ; chemistry ; metabolism ; pharmacology ; therapeutic use ; Drug Resistance, Multiple ; drug effects ; Drug Resistance, Neoplasm ; drug effects ; Female ; Humans ; Immunoconjugates ; chemistry ; Liver Neoplasms ; drug therapy ; metabolism ; pathology ; Mice ; Mice, Nude ; Nanoparticles ; chemistry
9.Expression and clinical significance of telomerase hTRT in primary hepatocellular carcinoma.
Yong-jian ZHOU ; Xiang-fu ZHANG ; Hui-shan LU ; Chang-ming HUANG ; Fa-duan YANG ; Chuan WANG
Chinese Journal of Hepatology 2004;12(8):500-500
Adult
;
Biomarkers, Tumor
;
biosynthesis
;
Carcinoma, Hepatocellular
;
diagnosis
;
enzymology
;
DNA-Binding Proteins
;
Female
;
Humans
;
Liver Neoplasms
;
diagnosis
;
enzymology
;
Male
;
Prognosis
;
Telomerase
;
biosynthesis
;
genetics
10.Recent advances in the study of bioreductive drugs targeted tumor hypoxia.
Jing-Bao LIU ; Lei FU ; Yong-Zhou HU ; Fa-Qin JIANG
Acta Pharmaceutica Sinica 2009;44(7):695-702
Tumor hypoxia is the necessary process in the development of solid tumors, which is the key factor for drug resistance, recurrence, attack and shift of tumor. Hypoxic tumor cells have a certain extent of tolerance to radiation and chemotherapy. Tumor hypoxia is an important target for medication therapy. In the recent years, the bioreductive drugs targeted tumor hypoxia has made great process in the treatment of tumors. The latest advances of bioreductive drugs targeted hypoxia were reviewed in this paper.
Antineoplastic Agents
;
therapeutic use
;
Cell Hypoxia
;
Humans
;
Hypoxia
;
Neoplasms
;
drug therapy
;
Quinones
;
therapeutic use
;
Reducing Agents
;
therapeutic use